Ibogaine is associated with a particularly important cardiac concern: its pharmacology can affect cardiac ion channels, including hERG potassium channels, which are involved in cardiac electrical repolarization. This can contribute to QT-interval prolongation and dangerous rhythm disturbances in susceptible circumstances. The U.S. Food and Drug Administration’s discussion of abnormal heart rhythms and QT prolongation provides useful context for why medication review and cardiac history matter when a substance can affect cardiac conduction.
Psilocybin is generally discussed through a different acute-risk profile. It acts primarily through serotonergic signaling, including 5-HT2A receptor activity. In supervised research settings, acute effects can include anxiety, fear, confusion, elevated blood pressure, nausea, and transient distress. It may also interact with serotonergic medicines; serotonin syndrome is a recognized toxic state associated with excessive serotonergic activity, although a medication list alone cannot establish an individual’s risk.
Neither profile is reducible to a single number or a simple “safer” label. Trial participants are usually screened, monitored, and selected under protocols that do not necessarily resemble informal, underground, or poorly regulated settings. The safety framework described across the comparison tools and topic guides is therefore best used to frame questions, not to decide that any experience is appropriate.
